Download Files:
SB 239063
$55 – $770
Products Details
Product Description
– SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC50 of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD[1][2].
Web ID
– HY-11068
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C20H21FN4O2
References
– [1]Underwood DC, et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther. 2000 Apr;293(1):281-8.|[2]Matthew Huentelman, et al. Methods of treating memory loss and enhancing memory performance. US 20120245188 A1.
CAS Number
– 193551-21-2
Molecular Weight
– 368.40
Compound Purity
– 99.61
SMILES
– COC1=NC=CC(C2=C(N=CN2[C@H]3CC[C@H](O)CC3)C4=CC=C(F)C=C4)=N1
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 33.33 mg/mL (ultrasonic)
Target
– Autophagy;p38 MAPK
Pathway
– Autophagy;MAPK/ERK Pathway
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
